Sclerostin domain-containing protein 1 (SOSTDC1), also known as USAG-1 or WISE, is a critical dual antagonist of both the BMP and Wnt signaling pathways. Positioned at the intersection of tissue regeneration and oncology, SOSTDC1 has emerged as a premier target for tooth regeneration (congenital anodontia) and renal tissue repair. Developing high-affinity therapeutics requires precise molecular tools that preserve native conformation and disulfide-rich folding.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SOSTDC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOSTDC1 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View SOSTDC1 Products |
| Gene Delivery | SOSTDC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View SOSTDC1 Products |
| Benchmark Ab | Anti-SOSTDC1 Recombinant Antibody Recombinant positive control derived from clinical-stage sequences. |
View SOSTDC1 Products |
| Validator | SOSTDC1 siRNA Set For target knockdown and specificity validation. |
View SOSTDC1 Products |
| Related Target A | BMP4 Direct binding partner of SOSTDC1; critical for BMP signaling rescue assays. |
View BMP4 Products |
| Related Target B | LRP6 Wnt co-receptor; SOSTDC1 competes with Wnt ligands for LRP5/6 binding. |
View LRP6 Products |
| Related Target C | SOST (Sclerostin) High-homology family member; essential for counter-screening to avoid off-target toxicity. |
View SOST Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation & glycosylation for binding assays | HEK293 mammalian expression system preserves complex disulfide-bonded cysteine knot structures. |
| Off-target cross-reactivity screening (SOST/Sclerostin) | High-purity SOST (Sclerostin) recombinant proteins available for precise selectivity profiling. |
| Lack of standardized screening controls | Sequence-verified clinical benchmark antibodies (biosimilars) included in our catalog. |
| In vitro validation of pathway rescue | Validated siRNA sets and high-titer lentiviral particles for robust cell-based functional assays. |
Live SOSTDC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SOSTDC1 therapeutics is intensifying, with major players shifting focus from basic academic research to clinical-stage monoclonal antibodies. As first-generation therapies targeting congenital tooth agenesis (anodontia) enter Phase I trials, the next wave of R&D is expanding into chronic kidney disease (CKD) and bone remodeling disorders. Because SOSTDC1 acts as a local tissue brake on regeneration, systemic administration requires highly localized delivery or highly specific antibodies to prevent off-target bone density abnormalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Toregem Biopharma, Kyoto University | Tooth Agenesis / Anodontia, Tooth Regrowth | BMP/Wnt pathway rescue assays (Requires native SOSTDC1 and BMP4/7 proteins) |
| mAbs / Soluble Receptors | Roche, Academic Medical Centers | Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD) | LRP6/BMP7 binding competition assays (Requires high-purity LRP6 and SOSTDC1) |
| Gene & Cell Therapies | Biotech Startups | Bone Regeneration, Periodontitis | Stable cell line development (Requires high-titer Lentivirus Premade Particles) |